Stemline Therapeutics Patent-Cliff Exposure & CMS Drug Spending Portfolio

Stemline Therapeutics (US): 2 reconciled FDA prescription therapies, $294.7M 2024 CMS Part D & Medicaid spend, and $21,369 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2038-01-01
2024 CMS Total Public Spend$294.7M
2024 Medicare Part D Spend$258.8M
2024 Medicaid Spend$35.9M
California HCAI SB 17 FilingsSpecialty launch notice ($21,369 intro WAC)